2003 and BioTech - Connected Health Pulse

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

JANUARY 18, 2019

back in 2003 — so we’ve known for over 16 years that in the U.S., From 2003 to 2019, the theory that prices are the primary driver of America’s spending more on health care than any other country is still the case. Two news items illustrate this issue in real time.

BioTech

BioTech Medicare Medical Billing Patient Experience

Will Foot Ulcer Treatment Survive Medicare Rollback?

Insulin Nation

DECEMBER 18, 2013

A 2003 study on Dermagraft undertaken throughout 35 U.S. In a recent Fierce Biotech article, CEO MacKay warned his staff of “heartbreaking” staff cuts to make the new pricing structure work. to 26.3%) as traditional wound care in closing diabetic foot ulcer wounds during a 12-week test period, for example.

Medicare

Medicare BioTech Pharmaceuticals

The Funding Spree for Neuroscience Startups: Venture Capital, Angel Investors, and Big Pharma betting big on Neuroscience

Lloyd Price

NOVEMBER 2, 2018

Pfizer aims to invest $150 million in biotech startups focused on neurometabolic disorders, neurodegeneration, and neuroinflammation. As of June 2018, the DDF has $350 million in funds and a portfolio of 16 investments focused on early intervention and treatment for dementia.

BioTech

BioTech Pharmaceuticals

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Will Foot Ulcer Treatment Survive Medicare Rollback?

The Funding Spree for Neuroscience Startups: Venture Capital, Angel Investors, and Big Pharma betting big on Neuroscience

Stay Connected